Join the 13th EGA-European Biosimilars Group Conference and increase your knowledge of this very promising field.

Over the years, this event has become the annual gathering of the world’s leading biosimilars experts, attracting Drug Regulatory Authorities, Academia, Healthcare Professionals and Industry representatives from all around the globe. This international conference provides a unique opportunity to hear and learn from leading experts in the biosimilars space, to discuss the current key topics, to get an update of the latest regulatory and market developments as well as to network with colleagues and new contacts during one of the networking events in London.  

KEY TOPIC: The science of extrapolation of indications, explained by EU regulators

• Biological and biosimilar medicines market: current status and future outlook
• Biosimilars: the European Commission industrial policy strategy and “Tajani initiative” follow-up
• Biosimilars evolving landscape: insight into market access
• Biosimilars uptake: best practice sharing by key EU member states
• Debate on GfK study findings: a multi-stakeholder approach in support of the biosimilar medicines market sustainability
• Real World Evidence sharing
• The science of extrapolation of indications, explained by EU regulators 
• Biosimilars naming and labelling regime: the European experience
• WHO Biological Qualifier Scheme: status of the proposal
• Biosimilar medicines approvals and scientific guidelines latest developments: the EMA overview
• Biosimilars global development: WHO and National Drug Regulatory Authorities role 
• Biosimilars: news from the US/FDA
• The biosimilarity concept: bringing it closer to patients, healthcare professionals and medical societies